✦ LIBER ✦

Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase

✍ Scribed by Hao Jiang; Shan-Shan Chen; Bin Jiang; Qian Jiang; Ya-Zhen Qin; Yue-Yun Lai; Xiao-Jun Huang

Publisher: Springer
Year: 2010
Tongue: English
Weight: 146 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-010-1031-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

XPC genetic polymorphisms correlate with

XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia

✍ Vicent M. Guillem; Francisco Cervantes; Jesús Martínez; Alberto Alvarez-Larrán; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Sustained remissions and low rate of BCR

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up

✍ Georg Hess; Ralf G. Meyer; Brigitte Schuch; Katja Bechthold; Ilse El-Kholy; Chri 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 3 views

Results of triple therapy with interfero

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase

✍ Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract ## BACKGROUND Before the discovery of imatinib mesylate, a Bcr‐Abl selective tyrosine kinase inhibitor, three agents, interferon‐alpha (IFN‐α), cytarabine (ara‐C), and homoharringtonine (HHT), had demonstrated activity against Philadelphia chromosome (Ph)‐positive chronic myelogenous l

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views

Significance of suboptimal response to i

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 2 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during